Medicare Limits Coverage of $28,000-a-Year Alzheimer’s Drug

WASHINGTON (AP) – Medicare says it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned.

Tuesday’s decision from the Centers for Medicare and Medicaid Services is a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.

It means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression of dementia.

Biogen said Tuesday that it disagrees with the Medicare decision.

By Ricardo Alonso-Zaldivar, Associated Press

About Brendan Fitzpatrick

Brendan, a recent graduate from the University of Massachusetts Amherst, is one of the newest members of the CapeCod.com NewsCenter team. When not on the beat, you'll probably find him watching Boston sports.



CapeCod.com
737 West Main Street
Hyannis, MA 02601
Contact Us | Advertise Terms of Use 
Employment and EEO | Privacy